Mansukh Mandaviya addresses 37th STOP TB Partnership Board Meeting

Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Submission to be reviewed under FDA real-time oncology review and Project Orbis

100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh

Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Lily announces positive gene therapy result for genetic hearing loss

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial